Ramucirumab as a Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: a Meta-Analysis of Randomized Clinical Trials [†]

Irena Ilic[1],*, Milena Ilic[2]

[1] Faculty of Medicine, University of Belgrade, Dr. Subotica 8, Belgrade 11000, Serbia; ajrini10@gmail.com

[2] Department of Epidemiology, Faculty of Medical Sciences, University of Kragujevac, S. Markovica 69, Kragujevac 34000, Serbia; drmilenailic@yahoo.com

* Correspondence: ajrini10@gmail.com; Tel.: +381-11-3636300

[†] Presented at the 1st International Electronic Conference on Biomedicine, 1–26 June 2021; Available online: https://ecb2021.sciforum.net/.

Abstract: Improvement of treatment outcomes in patients with locally advanced or metastatic urothelial carcinoma represents an important unmet need, since survival remains poor in patients who progressed after first-line treatment. The purpose of this study was to investigate the effects of ramucirumab, a human monoclonal antibody which binds to VEGFR-2, in the treatment of locally advanced or metastatic urothelial carcinoma. A literature search of PubMed and CENTRAL was conducted. Outcomes of interest were overall survival (OS), progression-free survival (PFS) and rate of adverse events. Time-to-event outcomes were combined using the generic inverse-variance method and presented as hazard ratio (HR) with 95% confidence intervals (95% CI), while dichotomous events were combined using the Mantel-Haenszel method and presented as odds ratio (OR) with 95% CI. All analyses were performed in RevMan 5.3. Literature search identified two randomized controlled trials. Addition of ramucirumab to docetaxel resulted in a statistically significant improvement in PFS (HR = 0.55, 95% CI 0.31–0.96, p = 0.030), while the difference was not significant for OS (HR = 0.86, 95%CI 0.71–1.04, p=0.12). Subgroup analysis by sex, age (<65 and ≥65 years), baseline hemoglobin (<10 g/dL and ≥10 g/dL), presence of visceral metastases and presence of liver metastases did not identify a subgroup in which improvement in OS was present. The difference in treatment-related grade ≥3 adverse events was not significant (OR = 1.47, 95%CI 0.95–2.27, p = 0.08). Ramucirumab in addition to docetaxel significantly improved PFS in patients with locally advanced or metastatic urothelial carcinoma. Future studies are necessary to identify a subset of patients who might have a significant improvement in OS.

Keywords: urothelial carcinoma; ramucirumab; overall survival; progression-free survival; meta-analysis

1. Introduction

In 2017, 2.63 million people had bladder cancer and 200,000 died from this disease worldwide [1]. Global projections indicate that by 2030 many countries, including the most developed like Switzerland, Germany, France, Japan, Canada, will experience a rise in bladder cancer incidence rates [2]. Therefore, stronger efforts aimed at prevention and improved treatment outcomes are of outmost importance.

Patients with locally advanced or metastatic urothelial carcinoma who have progressed following first-line platinum-based chemotherapy regimens have poor prognosis with median survival of 5 to 7

months [3,4]. Options for second-line treatment most often include single-agent chemotherapy or immunotherapy. Currently, the National Cancer Comprehensive Network guidelines recommend pembrolizumab, nivolumab, avelumab or erdafitinib for second-line treatment in patients progressing after platinum-based regimens [4]. However, the reported objective response rates and survival benefits and safety profile of these targeted therapies warrant a need for other treatment options.

Ramucirumab is an IgG1 human monoclonal antibody which binds to the vascular endothelial growth factor receptor 2 (VEGFR-2) and inhibits the VEGF pathway [5]. Research shows a promising role of VEGF-inhibitors in the population of patients with platinum-refractory advanced urothelial carcinoma [6].

The purpose of this study was to investigate the effects of ramucirumabin the treatment of locally advanced or metastatic urothelial carcinoma in patients previously treated with platinum-based chemotherapy.

2. Materials and Methods

The present meta-analysis was conducted in accordance with Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines [7].

2.1. Literature Search

We performed a literature search of PubMed and CENTRAL from inception to February 2021. We searched these databases using the following keywords: "ramucirumab" AND "urothelial" AND ("cancer" OR "neoplasm" OR "tumour"). Snowballing technique was applied to further identify relevant studies by searching reference lists of retrieved studies and reviews. There were no language restrictions.

2.2. Inclusion and Exclusion Criteria

Both authors screened titles and abstracts of all articles identified through literature search. Full texts of relevant studies were independently assessed by both authors. Inclusion criteria were: study designed as a randomized controlled trial, conducted in humans. Studies conducted in animals, observational studies, case reports and reviews were excluded. Authors resolved disagreements through consensus. In cases of multiple published reports of the same study, the most recent publication and the one containing most data was used.

2.3. Data Extraction and Study Quality Appraisal

The outcomes of interest were overall survival, progression-free survival and occurrence of treatment-related grade ≥3 adverse events. Quality of included studies was assessed using the National Heart, Lung, and Blood Institute's study quality assessment tool for controlled intervention studies which contains 14 questions regarding study design, statistical analysis and sources of bias [8].

2.3. Statistical Analysis

Time-to-event outcomes were combined using the generic inverse-variance method and presented as hazard ratio (HR) with 95% confidence intervals (95% CI). Dichotomous events were combined using the Mantel-Haenszel method and presented as odds ratio (OR) with 95% CI. Pooled HRs and ORs are graphically presented as forest plots. Based on the level of heterogeneity, a random effects model (DerSimonian and Liard) or a fixed effects model was applied. For heterogeneity assessment, I^2 statistic was used (moderate 30–60%, substantial 50–90% and considerable 75–100%) [9].

Subgroup analyses were planned for OS and PFS according to sex, age (<65 and ≥65 years), baseline hemoglobin (<10 g/dL and ≥10 g/dL), presence of visceral metastases and presence of liver metastases in order to further analyze heterogeneity. The p-value was considered significant at $p < 0.05$. All analyses were performed in RevMan 5.3 [10].

3. Results and Discussion

3.1. Literature Search and Study Characteristics

Literature search identified two randomized clinical trials. The flow diagram of literature search is shown in Figure 1. Study by Petrylak et al. (2016) was an open-label phase II trial which included 140 patients with locally advanced or metastatic urothelial carcinoma randomized to receive docetaxel, docetaxel plus ramucirumab or docetaxel plus icrucumab [5]. Study by Petrylak et al. (2020) was a double-blind phase III trial which included 530 patients randomized to receive ramucirumab plus docetaxel or placebo plus docetaxel [3]. Quality of included studies was satisfactory (Table 1).


Figure 1. Flow diagram of literature search.

**Table 1.** Characteristics of included studies.

Author, year [ref.]	Study design	Experimental group (No of patients)	Control group (No of patients)	OS (experimental *vs* control group)	PFS (experimental *vs* control group)	Assessed quality score [1]
Petrylak, 2016 [5]	Randomized, controlled, open-label, phase II trial	Ramucirumab + docetaxel (46)	Docetaxel (45)[2]	10.4 *vs* 9.2 months	5.4 *vs* 2.8 months	10
Petrylak, 2020 [3]	Randomized, controlled, double-blind, phase III trial	Ramucirumab + docetaxel (263)	Placebo + docetaxel (267)	9.4 *vs* 7.9 months	4.1 *vs* 2.8 months	14

[1]According to the National Heart, Lung, and Blood Institute's study quality assessment tool for controlled intervention studies. [2]The trial had a third arm (docetaxel + icrucumab) which data were not included in the

analysis because in the published data outcomes of this group were given in reference to the control group (docetaxel) which did not contain ramucirumab. Legend: OS – overall survival; PFS – progression-free survival.

3.2. Overall Survival, Progression-free Survival and Rate of Adverse Events

There was no statistically significant improvement in OS in patients receiving ramucirumab plus docetaxel compared to docetaxel alone (HR = 0.86 [95% CI 0.71–1.04], p=0.12) (Figure 2 (a)). Subgroup analysis by sex, age (<65 and ≥65 years), baseline hemoglobin (<10 g/dL and ≥10 g/dL), presence of visceral metastases and presence of liver metastases did not identify a subgroup in which improvement in OS was present (data not shown). Addition of ramucirumab significantly improved PFS in patients with advanced or metastatic urothelial carcinoma (HR = 0.55 [95% CI 0.31–0.96], *p* = 0.03) (Figure 2 (b)). Subgroup analysis for PFS was not possible because only one of the two studies reported this data. There was no statistically significant difference in the rate of treatment-related grade ≥3 adverse events with the addition of ramucirumab (OR = 1.47 [95% CI 0.95–2.27], *p* = 0.08) (Figure 2 (c)).

(**a**)

(**b**)

(**c**)

Figure 2. Forest plot of the effects of the addition of ramucirumab in the treatment of locally advanced or metastatic urothelial carcinoma on: (**a**) overall survival; (**b**) progression-free survival; (**c**) adverse events.

4. Discussion

Our study found a significant improvement in PFS (HR = 0.55 [95% CI 0.31–0.96], *p* = 0.03) with the addition of ramucirumab in patients with locally advanced or metastatic urothelial carcinoma without an increase in safety concerns (treatment-related grade ≥3 adverse events OR = 1.47 [95% CI 0.95–2.27], *p* = 0.08). However, the improvement in OS was not statistically significant (HR = 0.86 [95% CI 0.71–1.04], *p* = 0.12).

About 5% of patients with urothelial carcinomas are diagnosed at the metastatic stage of disease, while approximately 50% of those diagnosed at earlier stages who have received treatment relapse [4]. Given the poor prognosis in these patients, therapeutic options which enhance survival are necessary.

Our study showed that the addition of ramucirumab to docetaxel increased PFS but showed no significant difference in OS compared to the control group. Similar results have been found for bevacizumab, which improved PFS but not OS when added to cisplatin and gemcitabine [11]. Possible explanation includes the fact that two trials were designed so that the sample-size and study power were based on detecting a PFS difference. Research shows that in this group of patients improvements in PFS predict improvements in OS [12]. However, another agent – pembrolizumab, showed significant improvement in OS in this treatment setting, but no difference in median PFS [13]. Therefore, future research could go in the direction of investigating possibilities for combination of VEGF-inhibitors and immunotherapy.

Our study did not show a significant increase in treatment-related grade ≥3 adverse events in patients receiving ramucirumab, compared to another anti-VEGF agent bevacizumab which showed a statistically significant increase in occurrence of deep vein thrombosis and pulmonary embolism [6]. This is particularly important given that the median age at diagnosis of patients with bladder cancer is 73 years [4], therefore there are many concomitant medical conditions in these individuals which make treatment of this disease challenging.

Our results indicate a need for further research of biomarkers and patient characteristics which would help identify those subgroups to benefit the most from the addition of ramucirumab, as well as a need for research into the possibilities of combining VEGF-inhibitors such as ramucirumab and immunotherapy agents.

4.1. Strengths and Limitations

To the best of our knowledge, this is the first meta-analysis which investigated the effects of ramucirumab in patients with locally advanced or metastatic urothelial carcinoma. The quality of included studies was satisfactory. However, our study had several limitations. First, the number of included studies is only two due to the novelty of investigated therapeutic regimen for this indication. Due to this, we could not analyze presence of publication bias. Further, we were not able to perform a planned subgroup analysis for PFS due to the lack of published data.

5. Conclusions

Addition of ramucirumab to docetaxel in platinum-refractory patients with locally advanced or metastatic urothelial carcinoma improves PFS without increasing the rate of grade ≥3 adverse events. However, there was no benefit in OS. Further well-designed clinical trials are necessary to investigate effects on OS and whether any subgroups of patients could see an improvement with this treatment regimen.

Author Contributions: Conceptualization, I.I. and M.I.; methodology, I.I. and M.I.; software, I.I. and M.I.; validation, I.I. and M.I.; formal analysis, I.I. and M.I.; investigation, I.I. and M.I.; resources, I.I. and M.I.; data curation, I.I. and M.I.; writing—original draft preparation, I.I. and M.I.; writing—review and editing, I.I. and M.I.; visualization, I.I. and M.I.; supervision, M.I.; project administration, I.I. and M.I.

Conflicts of Interest: The authors declare no conflict of interest.

References

1.   He H, Xie H, Chen Y, Li C, Han D, Xu F, Lyu J. Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study. *BMC Public Health*. **2020**, *20*, 1–9, doi: 10.1186/s12889-020-09835-7.

The 1st International Electronic Conference on Biomedicine, 1–26 June 2021.

2. Wong MC, Fung FD, Leung C, Cheung WW, Goggins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. *Sci Rep*. **2018**, *8*, 1–12, doi: 10.1038/s41598-018-19199-z.

3. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Evan YY. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. *Lancet Oncol*. **2020**, *21*, 105–120, doi: 10.1016/S1470-2045(19)30668-0.

4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Bladder cancer, version 3.2021. Available online: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (accessed on 30 April 2021).

5. Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial. *J Clin Oncol*. **2016**, *34*, 1500–1509, doi: 10.1200/JCO.2015.65.0218.

6. Ghafouri S, Burkenroad A, Pantuck M, Almomani B, Stefanoudakis D, Shen J, Drakaki A. VEGF inhibition in urothelial cancer: the past, present and future. *World J Urol*. **2021**, *39*, 741–749, doi: 10.1007/s00345-020-03213-z.

7. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. **2009**, *6*, e1000097, doi: 10.1371/journal.pmed.1000097.

8. National Institutes of Health. Quality Assessment of Controlled Intervention Studies. Available online: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools(accessed on 10 March 2021).

9. Higgins JPT and Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration. Available online: www.handbook.cochrane.org (accessed on 10 March 2021).

10. RevMan. 2014 [Computer program] Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

11. Rosenberg JE, Ballman KV, Halabi S, Watt C, Hahn OM, Steen PD, Dreicer R, Flaig TW, Stadler WM, Sweeney C, Mortazavi A. CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. *J Clin Oncol*, **2019**, *37*, 4503–4503, doi: 10.1200/JCO.2019.37.15_suppl.4503.

12. Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. *Clin Genitourin Cancer*, **2014**, *12*, 130–137, doi:10.1016/j.clgc.2013.09.002.

13. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. *J Clin Oncol*. **2009**, *27*, 4454–4461, doi: 10.1200/JCO.2008.20.5534.